# SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

> **NCT06269120** · — · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 470 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Oral Semaglutide

## Key facts

- **NCT ID:** NCT06269120
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 470 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06269120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06269120, "SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06269120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*